Boca Raton,FL July 28, 2010 –THE STOCK WIZARDS FOCUS LISTS INCLUDES: (OTCBB: ACTC ) Advanced Cell Technology, Inc. (OTCBB: ADLS) Advanced Life Sciences Holdings, Inc., (AMEX: AEZ) American Oil & Gas, Inc. (NYSE: AHD) Atlas Pipeline Holdings L.P.
Learn to Trade Small Cap Penny Stocks from Expert Traders. Visit The TSW Website at http://www.TheStockWizards.net learn to make big profits.
Receive Our Hot OTC Newsletter Put out Every Weekend Highlighting Penny Stocks, Small Cap & Micro Cap Stocks before They Breakout. The Hottest weekend Newsletter Around.
+++++++++++++++++++++++
(OTCBB: ACTC — Advanced Cell Technology, Inc.)
CURRENT NEWS!!
MARLBOROUGH, Mass., Jul 28, 2010 — Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company’s plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). In November 2009, ACT filed an Investigational New Drug (IND) Application to commence treating patients. ACT believes the design of its product and the choice of SMD, from a safety standpoint, represents an ideal cellular product to gain early experience and knowledge about ES cell safety.
The additional details submitted to the FDA support the Company’s belief that the product would be safe and well tolerated by patients. The Company’s process for differentiating ES cells to retinal pigmented epithelial (RPE) cells is not permissive to ES cell persistence in the culture. In fact, no stem cells could be detected even when the RPE cells were spiked during culture with up to 10 percent ES cells. “Our batch release assay has a level of detection of less than 0.0001% for ES cell contamination of RPE cell cultures,” said Robert Lanza, M.D., Chief Scientific Officer at ACT. “We can detect a single stem cell in over a million RPE cells. This is especially significant considering the small number of cells (50,000 to 200,000) to be administered into a controlled space in the eye. Stem cells can’t persist in our culture process, and therefore do not pose a risk of contamination of the final RPE cells to be transplanted.”
ACT’s animal models were designed to assess the safety of cells in the injected eyes. The response to the FDA provides additional data to address the specific concerns presented by the Agency. In addition, studies for tumorigenicity and safety/biodistribution were extended to the lifetime of the animals. The implanted RPE cells survived long-term in the eyes of animals, and no tumors formed as a consequence to the implanted cells. No other adverse findings associated with treatment with RPE cells were observed from histological or pathological evaluation of the animals. “We observed kinetics typical for successful transplantation of the cells,” said Edmund V. Mickunas, ACT’s Vice President of Regulatory. “Histology at all time point’s revealed persistence of human cells without inflammation or immune cell infiltration; and, without tumor formation.”
“We are extremely encouraged by this product opportunity, both in terms of safety and efficacy,” said William M. Caldwell IV, ACT’s Chairman and CEO. “We did not observe any tumorigenicity or adverse abnormal findings. We believe the inherent capability of our manufacturing process to inhibit the presence of hES cells, and the fact that the level of detection in the final batch is less than one ES cell per million, support the safety of using RPE cells in a Phase I/II Clinical Trial in humans.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Technical Outlook:
ATCT Traders and Investors feel the stock is at a short term bottom and are smartly accumulating. A breakout above the 10 day moving average will confirm the bottom reversal. ACTC is currently up 4.41% on heavy volume of 1.9 million shares in the morning session.
+++++++++++++++++++++++++++++
(OTCBB: ADLS— Advanced Life Sciences Holdings, Inc.)
Current News !!
Advanced Life Sciences Applies for FDA Fast-Track Designation for Restanza in CABP
CHICAGO, July 28, 2010 /– Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for Fast-Track designation for Restanza(TM), a novel once-daily oral antibiotic, for the treatment of community acquired bacterial pneumonia (CABP).
(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
Fast Track designation by the FDA is a process designed to expedite the review of new drugs that treat serious diseases and fill an unmet medical need. If there are existing therapies, a fast track drug must show some advantage over available treatment, such as superior effectiveness or avoiding serious side effects of an available treatment. A drug that receives Fast Track designation is eligible for benefits that include:
More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval
Eligibility for FDA Accelerated Approval, i.e., approval on an effect on a surrogate, or substitute endpoint reasonably likely to predict clinical benefit
Rolling Review, which means that a drug company can submit completed sections of its New Drug Application (NDA) for review by FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed. NDA review usually does not begin until the drug company has submitted the entire application to the FDA.
In addition, most drugs that are eligible for Fast Track designation are likely to be considered appropriate to receive a Priority Review.
According to recent mortality data from the Centers for Disease Control and Prevention (CDC), pneumonia remains the leading cause of death for infectious disease in the U.S., accounting for over 55,000 deaths annually. Treatment of the disease is compounded by increasing rates of resistance to currently prescribed antibiotics. Recent surveillance data demonstrate that the primary etiologic pathogen, Streptococcus pneumoniae, has resistance rates approaching 40% for macrolides.
The Company believes that Restanza fulfills an unmet medical need in that it displays superior in vitro and in vivo efficacy against macrolide-resistant Streptococcus pneumoniae (MRSP) compared to macrolides, that it is also active against fluoroquinolone-resistant S. pneumoniae; and that it possesses a potentially better safety profile compared to existing oral antibiotics that may be used to treat MRSP infection in patients with CABP.
A clinical trial protocol using a superiority design to assess the safety and efficacy of Restanza compared to azithromycin in CABP patients with MRSP is currently being finalized in close collaboration with FDA under the Special Protocol Assessment (SPA) process.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.
+++++++++++++++++++++++++++++
(AMEX: AEZ — American Oil & Gas, Inc.)
Current News !!
Hess announces acquisition of American Oil & Gas Inc under merger agreement
Jul 28, 2010 — Energy company Hess Corporation (NYSE:HES) on Tuesday reported that American Oil & Gas will be acquired by it under a merger agreement approved by both companies’ boards of directors, in an all-stock transaction.
The company further said that with the acquisition of the oil and gas company its acreage position in the Bakken oil play in North Dakota increases by about 85,000 net acres.
Hess will issue 0.1373 common shares in exchange for each outstanding American’s common share, pursuant to the agreement, representing a 9.4% premium to American’s stockholders based on the closing stock prices of both companies’ shares on Tuesday.
Under the net settlement, Hess will issue about 8.6m shares for all outstanding American shares and options; a possible cash dividend to American’s stockholders, subject to certain conditions; and provide a USD30m working capital credit facility to fund American’s exploration and production activities and other working capital needs before close of the transaction.
The acting financial advisor to Hess in this transaction is Goldman, Sachs & Co while Tudor Pickering Holt & Co Securities Inc is acting financial advisor and provided a Fairness Opinion to American. Legal counsel is being provided for Hess by White & Case LLP and for American by Patton Boggs LLP.
+++++++++++++++++++++++++++
(NYSE: AHD — Atlas Pipeline Holdings L.P.)
CURRENT NEWS!!
Atlas Pipeline Partners, L.P. and Atlas Pipeline Holdings, L.P. to Report Operating Results for Second Quarter 2010 and to Host Earnings Conference Call
PHILADELPHIA, Jul 27, 2010 — Atlas Pipeline Partners, L.P. (NYSE:APL) and Atlas Pipeline Holdings, L.P. (NYSE:AHD) announced today that they will release their second quarter 2010 results after market hours on Monday, August 2, 2010, and invites investors and other interested parties to listen to the live webcast of Atlas Pipeline Partners, L.P.’s quarterly conference call on Tuesday, August 3, 2010, at 9:00 a.m. Eastern Time.
This call is being webcast live and can be accessed by investors and other interested parties in the Investor Relations section of Atlas Pipeline’s website at www.atlaspipelinepartners.com. For those unavailable to listen to the live broadcast, the replay of the webcast will be available following the live call on the Atlas Pipeline Partners website and telephonically beginning at 12:00 p.m. on August 3, 2010 by dialing 888-286-8010, passcode: 11134056.
Atlas Pipeline Partners, L.P. is active in the transmission, gathering and processing segments of the midstream natural gas industry. In the Mid-Continent region of Oklahoma, Arkansas, southern Kansas, northern and western Texas and the Texas panhandle, APL owns and operates eight active gas processing plants and a treating facility, as well as approximately 7,900 miles of active intrastate gas gathering pipeline. In Appalachia, APL is a 49% joint venture partner with Williams in Laurel Mountain Midstream, LLC, which manages the natural gas gathering system in that region, namely from the Marcellus Shale in southwestern Pennsylvania. For more information, visit the Partnership’s website at www.atlaspipelinepartners.com or contact investorrelations@atlaspipelinepartners.com.
Atlas Pipeline Holdings, L.P. is a limited partnership which owns and operates the general partner of Atlas Pipeline Partners, L.P., through which it owns a 2% general partner interest, all the incentive distribution rights and approximately 5.8 million common units of Atlas Pipeline Partners.
+++++++++++++++++++++
About TheStockWizards.net
Please visit our website for Disclosures and Disclaimers and any conflicts of interest that there may be. http://thestockwizards.net/about/disclaimer/
Forward-Looking Statement: This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
TheStockWizards.net is not a registered investment advisers or broker/dealer.
TheStockWizards.net makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high risk.
Contact Info: E-mail: info@ thestockwizards.net
TheStockWizards.net 954-592-4770
